Introduction：Basic information about CAS 119687-33-1|Iganidipine, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Iganidipine |
|---|
| CAS Number | 119687-33-1 | Molecular Weight | 526.62500 |
|---|
| Density | 1.164g/cm3 | Boiling Point | 641.5ºC at 760mmHg |
|---|
| Molecular Formula | C28H38N4O6 | Melting Point | / |
|---|
| MSDS | / | Flash Point | 341.8ºC |
|---|
Names
| Name | 5-O-[2,2-dimethyl-3-(4-prop-2-enylpiperazin-1-yl)propyl] 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate |
|---|
| Synonym | More Synonyms |
|---|
Iganidipine BiologicalActivity
| Description | Iganidipine is a Ca2+ antagonist. |
|---|
| Related Catalog | Signaling Pathways >>Membrane Transporter/Ion Channel >>Calcium ChannelResearch Areas >>Cardiovascular Disease |
|---|
| Target | Ca2+[1] |
|---|
| In Vivo | Iganidipine (0.03% solution) significantly increases optic nerve head (ONH) tissue blood velocity (NBONH) by 8 to 10% in treated eyes after a single administration (p<0.05) or by 18 to 35% after 7-, 14-, or 21-day twicedaily administration in rabbits (p<0.05). In monkeys, 0.03% and 0.1% Iganidipine significantly increases NBONH in treated eyes by 20 and 41% after 7-day (p<0.05) twice-daily administration, respectively[1]. |
|---|
| Animal Admin | Monkeys[1] Five adult cynomolgus monkeys (age, 5-8 years; weight, 3-5 kg; sex, 5 males) are used. All examinations are performed with the monkeys sitting in a modified monkey chair. On the first experimental day, after general anesthesia is induced by Ketamine hydrochloride at a dose of 8 to 10 mg/kg intramuscularly, pupil dilation is induced with one drop of Tropicamide in both eyes. The NBONH, IOP, blood pressure, pulse rate, SaO2, and body temperature are measured at 9AM. Starting on the 2nd experimental day, Iganidipine (0.03% or 0.1%, 30 mL) is administered in one randomly chosen eye and vehicle solution into the other eye twice daily at 8AM and 8PM for 7 days. At 9AM on the 8th experimental day, the same measurements are repeated after general anesthesia and bilateral pupil dilation. After a 4-week interval, a second series of experiments is performed using a different Iganidipine concentration according to the same time schedule. |
|---|
| References | [1]. Ishii K, et al. Iganidipine, a new water-soluble Ca2+ antagonist: ocular and periocular penetration after instillation. Invest Ophthalmol Vis Sci. 2003 Mar;44(3):1169-77. |
|---|
Chemical & Physical Properties
| Density | 1.164g/cm3 |
|---|
| Boiling Point | 641.5ºC at 760mmHg |
|---|
| Molecular Formula | C28H38N4O6 |
|---|
| Molecular Weight | 526.62500 |
|---|
| Flash Point | 341.8ºC |
|---|
| Exact Mass | 526.27900 |
|---|
| PSA | 116.93000 |
|---|
| LogP | 4.10340 |
|---|
| Vapour Pressure | 2.37E-16mmHg at 25°C |
|---|
| Index of Refraction | 1.548 |
|---|
| InChIKey | QBTSPDQKRVMTRU-UHFFFAOYSA-N |
|---|
| SMILES | C=CCN1CCN(CC(C)(C)COC(=O)C2=C(C)NC(C)=C(C(=O)OC)C2c2cccc([N+](=O)[O-])c2)CC1 |
|---|
Synonyms
| Iganidipine |
| UNII-9FPE98DLZ5 |
